Presynaptic congenital myasthenic syndromes: understanding clinical phenotypes through in vivo models
Abstract: Presynaptic congenital myasthenic syndromes (CMS) are a group of genetic disorders affecting the presynaptic side of the neuromuscular junctions (NMJ). They can result from a dysfunction in acetylcholine (ACh) synthesis or recycling, in its packaging into synaptic vesicles, or its subsequent release into the synaptic cleft. Other proteins involved in presynaptic endplate development and maintenance can also be impaired.
Presynaptic CMS usually presents during the prenatal or neonatal period, with a severe phenotype including congenital arthrogryposis, developmental delay, and apnoeic crisis. However, milder phenotypes with proximal muscle weakness and good response to treatment have been described. Finally, many presynaptic genes are expressed in the brain, justifying the presence of additional central nervous system symptoms.
Several animal models have been developed to study CMS, providing the opportunity to identify disease mechanisms and test treatment options. In this review, we describe presynaptic CMS phenotypes with a focus on in vivo models, to better understand CMS pathophysiology and define new causative genes
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Journal of neuromuscular diseases. - 10, 5 (2023) , 731-759, ISSN: 2214-3602
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2023
- Urheber
- DOI
-
10.3233/jnd-221646
- URN
-
urn:nbn:de:bsz:25-freidok-2366592
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pugliese, Alessia
- Holland, Stephen H.
- Rodolico, Carmelo
- Lochmüller, Hanns
- Spendiff, Sally
- Universität
Entstanden
- 2023
Ähnliche Objekte (12)
The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations
Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Correction to: Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era
Long term follow-up on pediatric cases with congenital myasthenic syndromes - a retrospective single centre cohort study
Mitochondrial mutations can alter neuromuscular transmission in congenital myasthenic syndrome and mitochondrial disease
Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome
Correction to: A guide to writing systematic reviews of rare disease treatments to generate FAIRcompliant datasets: building a Treatabolome
Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders
Biallelic PTPMT1 variants disrupt cardiolipin metabolism and lead to a neurodevelopmental syndrome
The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations
Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Correction to: Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era
Long term follow-up on pediatric cases with congenital myasthenic syndromes - a retrospective single centre cohort study
Mitochondrial mutations can alter neuromuscular transmission in congenital myasthenic syndrome and mitochondrial disease
Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome
Correction to: A guide to writing systematic reviews of rare disease treatments to generate FAIRcompliant datasets: building a Treatabolome
Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders
Biallelic PTPMT1 variants disrupt cardiolipin metabolism and lead to a neurodevelopmental syndrome
The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations
Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Correction to: Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era
Long term follow-up on pediatric cases with congenital myasthenic syndromes - a retrospective single centre cohort study
Mitochondrial mutations can alter neuromuscular transmission in congenital myasthenic syndrome and mitochondrial disease
Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome
Correction to: A guide to writing systematic reviews of rare disease treatments to generate FAIRcompliant datasets: building a Treatabolome
Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders